MeiraGTx Plc

(NASDAQ) MGTX

Current Price$12.44

Market Cap$1.14B

Since IPO (2018)-18%

5 Year-14%

1 Year+44%

1 Month+20%

MeiraGTx Plc last closing stock price
Metric	Price	Date
Last close	USD 12.44	2026-07-17

MeiraGTx Plc stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-7.09%	USD 13.39	2026-07-10
1 month	+19.5%	USD 10.41	2026-06-17
3 month	+22.92%	USD 10.12	2026-04-17
Year to date	+56.48%	USD 7.95	2025-12-31
1 year	+44.32%	USD 8.62	2025-07-17
3 year	+92.27%	USD 6.47	2023-07-18
5 year	-14.33%	USD 14.52	2021-07-16
Since inception	-17.8%	USD 15.00	2018-06-08

MeiraGTx Plc Financials at a Glance

Market Cap

$1.14B

Revenue (TTM)

$79.76M

Net Income (TTM)

-$120.53M

EPS (TTM)

-$1.49

P/E Ratio

-8.28

Dividend

$0.00

Beta (Volatility)

1.27 (Average)

Dividend

$0.00

Beta (Volatility)

1.27 (Average)

Price

$12.44

Volume

14,035

Open

$12.10

Price

$12.44

Volume

14,035

Open

$12.10

Previous Close

$12.44

Daily Range

$11.95 - $12.67

52-Week Range

$6.62 - $15.35

Estimated Earnings Date

Aug 13, 2026

Dividend

$0.00

Beta (Volatility)

1.27 (Average)

Price

$12.44

Volume

14,035

Open

$12.10

Previous Close

$12.44

Daily Range

$11.95 - $12.67

52-Week Range

$6.62 - $15.35

Estimated Earnings Date

Aug 13, 2026

MGTX News

Page 1

MGTX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MeiraGTx Plc

MeiraGTx makes genetic medicines for eye and brain diseases. These treatments help patients with blindness or dry mouth. Doctors can control these medicines using simple oral pills.

Pills and Gene Therapy

Salivary Gland Programs: Targeted therapies for dry mouth caused by radiation or autoimmune disorders.
Brain Disease Medicines: Treatments for Parkinson’s and other disorders affecting the nervous system.
Eye Care Pipeline: Portfolio of therapies for inherited blindness and age-related vision loss.
Riboswitch Technology: Control system allowing oral pills to regulate gene activity inside the body.

New Deals and AI Growth

Sold RPGR eye therapy assets to Johnson & Johnson Innovative Medicine in late 2023.
Formed a $430 million AI collaboration with Hologen in March 2025 for clinical data modeling.
Purchased cell therapy assets from Smart Immune in July 2025 to expand manufacturing capabilities.
Granted Eli Lilly rights to three eye disease programs in November 2025.
Licensed AI-designed protein inhibitors from ZipBio in December 2025 to treat eye inflammation.

Built-In Manufacturing Power

MeiraGTx operates its own manufacturing sites in London and Ireland to control drug quality. These facilities meet Good Manufacturing Practice (GMP) standards, which are strict quality rules for making medicines.

This internal network allows the company to produce materials for both clinical trials and commercial sales. It uses Adeno-Associated Virus (AAV), a safe viral shell, to deliver therapeutic genes to patients.

The 2025 Scorecard

Revenue hit $75.4 million in Q4 2025, up 252.3% from the prior year.
Net income reached $15.1 million in Q4 2025, improving from a $39.4 million loss.
Operating cash flow turned positive at $46.6 million in Q4 2025, up 300.3% year-over-year.
Free cash flow reached $39.9 million in Q4 2025, improving from a $24.5 million deficit.

Bottom Line

MeiraGTx has grown from a research firm into a producer of genetic medicines. Its internal labs and AI partnerships help it target common chronic diseases.

AI Generated • May 3, 2026

Industry

Biotechnology

Sector

Health Care

Employees

403

CEO

Alexandria Forbes, PhD

Website

meiragtx.com

Headquarters

New York City, NY 10016, US

MGTX Financials

Key Financial Metrics (TTM)

Gross Margin

91.64%

Operating Margin

-131.89%

Net Income Margin

-151.12%

Return on Equity

474.91%

Return on Capital

-127.84%

Return on Assets

-49.27%

Earnings Yield

-12.08%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.14B

Shares Outstanding

92.61M

Volume

14.04K

Avg. Volume

978.09K

Financials (TTM)

Gross Profit

$73.09M

Operating Income

-$105.19M

EBITDA

-$95.72M

Operating Cash Flow

$8.28M

Capital Expenditure

-$10.62M

Free Cash Flow

-$2.34M

Cash & ST Invst.

$71.54M

Total Debt

$87.53M

MeiraGTx Plc Performance Analysis

MeiraGTx Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 15,920,000	-57.8%
2023	2023-12-31	USD 14,017,000	-12.0%
2024	2024-12-31	USD 33,279,000	137.4%
2025	2025-12-31	USD 81,391,000	144.6%

MeiraGTx Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	91.6%
Q3	2025-09-30	-88.9%
Q4	2025-12-31	18281.5%
Q1	2026-03-31	-99.6%

MeiraGTx Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -2.87	59.2%
2023	2023-12-31	USD -1.49	-48.1%
2024	2024-12-31	USD -2.12	42.3%
2025	2025-12-31	USD -1.42	-32.9%

MeiraGTx Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	5.9%
Q3	2025-09-30	-29.2%
Q4	2025-12-31	130.6%
Q1	2026-03-31	-400.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$293.00K

-84.8%

Gross Profit

-$2.91M

-631.6%

Gross Margin

-9.94%

N/A

Market Cap

$1.14B

N/A

Market Cap/Employee

$2.79M

N/A

Employees

409

N/A

Net Income

-$46.31M

-15.8%

EBITDA

-$40.46M

-19.5%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$71.54M

+7.5%

Total Debt

$87.53M

+8.2%

Accounts Receivable

$17.96M

+243.7%

Inventory

$0.00

-100.0%

Long Term Debt

$60.41M

-22.1%

Short Term Debt

$27.13M

+722.7%

Return on Assets

-49.27%

N/A

Return on Invested Capital

-1.53%

N/A

Free Cash Flow

$15.80M

+141.0%

Operating Cash Flow

$17.81M

+148.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ABSIAbsci Corporation

ABSIAbsci Corporation$8.30+0.79%

REPLReplimune Group, Inc.

REPLReplimune Group, Inc.$10.23+7.46%

AVBPArriVent BioPharma, Inc.

AVBPArriVent BioPharma, Inc.$33.19+1.31%

MLTXMoonLake Immunotherapeutics

MLTXMoonLake Immunotherapeutics$19.68+3.52%

ARVNArvinas, Inc.

ARVNArvinas, Inc.$8.01-0.25%

DNAGinkgo Bioworks Holdings, Inc.

DNAGinkgo Bioworks Holdings, Inc.$7.91-4.58%

IOVAIovance Biotherapeutics, Inc.

IOVAIovance Biotherapeutics, Inc.$5.00+7.30%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ONDSOndas

ONDSOndas$6.53-0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.98-0.04%

INTCIntel

INTCIntel$95.04-0.02%

NOKNokia

NOKNokia$10.12-0.03%

PATHUiPath

PATHUiPath$12.15+0.01%

JOBYJoby Aviation

JOBYJoby Aviation$7.23-0.01%

SOFISoFi Technologies

SOFISoFi Technologies$17.28-0.00%

Questions About MGTX

What is the current price of MeiraGTx Plc?

MeiraGTx Plc is trading at $12.44 per share.

What is the 52-week range for MeiraGTx Plc?

Over the past 52 weeks, MeiraGTx Plc has traded between $6.62 and $15.35.

How much debt does MeiraGTx Plc have?

As of the most recent reporting period, MeiraGTx Plc reported total debt of $87.53M.

How much cash does MeiraGTx Plc have on hand?

MeiraGTx Plc reported $71.54M in cash and cash equivalents in its most recent financial results.

What is MeiraGTx Plc’s dividend yield?

MeiraGTx Plc does not currently have a dividend yield.

MeiraGTx Plc

MeiraGTx Plc Financials at a Glance

MGTX News

What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near

Who Owns ChatGPT? Largest Shareholders & Board of Directors

MeiraGTx Sales Jump 1,133 Percent

Why MeiraGTx Holdings Stock Is Down Today

3 Top Stocks Under $20

2 Small-Cap Biotechs With Huge Upside

Why McEwen Mining, MeiraGTx Holdings, and Electronic Arts Slumped Today

3 Small-Cap Biotech Stocks That Soared Last Week

MGTX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About MeiraGTx Plc

Pills and Gene Therapy

New Deals and AI Growth

Built-In Manufacturing Power

The 2025 Scorecard

Bottom Line

MGTX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

MeiraGTx Plc Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About MGTX

What is the current price of MeiraGTx Plc?

What is the 52-week range for MeiraGTx Plc?

How much debt does MeiraGTx Plc have?

How much cash does MeiraGTx Plc have on hand?

What is MeiraGTx Plc’s dividend yield?

Premium Investing Services